IRADIMED (IRMD) CEO-linked trust sells 2,500 shares under 10b5-1 plan

Rhea-AI Filing Summary

IRADIMED CORP director and CEO Roger E. Susi reported indirect open‑market sales of 2,500 shares of Common Stock through the Phillip Susi 2008 Dynasty Trust. The shares were sold on June 1, 2026 in multiple trades at weighted average prices between $88.68 and $91.91, under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 5, 2025.

After these sales, the Phillip Susi 2008 Dynasty Trust held 2,164,600 shares. Separate indirect holdings reported include 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust and 162,950 shares held by the Roger E. Susi Revocable Trust. Susi disclaims beneficial ownership beyond his pecuniary interest in these trust‑held shares.

Insider Trade Summary 10b5-1

Net Seller: 2,500 shares ($226,507)

Net Sell 6 txns

Insider Susi Roger E.

Role CEO, President, Chairman

Sold 2,500 shs ($227K)

Type	Security	Shares	Price	Value
Sale	Common Stock	400	$88.68	$35K
Sale	Common Stock	775	$89.79	$70K
Sale	Common Stock	401	$91.08	$37K
Sale	Common Stock	924	$91.91	$85K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,164,600 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

Shares sold: 2,500 shares Sale price (weighted average example): $91.91/share Post-sale holdings – Phillip Susi 2008 Dynasty Trust: 2,164,600 shares +3 more

6 metrics

Shares sold 2,500 shares Total Common Stock sold indirectly on June 1, 2026

Sale price (weighted average example) $91.91/share One reported weighted average sale price for June 1, 2026 trade

Post-sale holdings – Phillip Susi 2008 Dynasty Trust 2,164,600 shares Indirect Common Stock holdings after June 1, 2026 sales

Holdings – Matthew Susi 2008 Dynasty Trust 2,062,500 shares Indirect Common Stock holdings reported as of June 1, 2026

Holdings – Roger E. Susi Revocable Trust 162,950 shares Indirect Common Stock holdings reported as of June 1, 2026

Net share change -2,500 shares Net sell direction across reported non-derivative transactions

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, pecuniary interest, Section 16, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

pecuniary interest financial

"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"

Section 16 regulatory

"shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose."

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

indirect ownership financial

"direct_or_indirect: "I", nature_of_ownership: "By Phillip Susi 2008 Dynasty Trust""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FLORIDA 32826

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President, Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		400	D	$88.68(2)	2,164,600	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	06/01/2026		S(1)		775	D	$89.79(3)	2,163,825	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	06/01/2026		S(1)		401	D	$91.08(4)	2,163,424	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	06/01/2026		S(1)		924	D	$91.91(5)	2,162,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(6)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Roger E. Susi	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did IRMD insider Roger E. Susi report in this Form 4?

Roger E. Susi reported indirect sales of IRADIMED CORP stock. A trust associated with him sold 2,500 shares of Common Stock on June 1, 2026 under a Rule 10b5-1 plan, while significant indirect trust holdings remain reported.

How many IRMD shares were sold and at what prices in this filing?

A total of 2,500 IRADIMED shares were sold indirectly. The Phillip Susi 2008 Dynasty Trust executed several open-market sales at weighted average prices reported around $88.68 to $91.91 per share on June 1, 2026.

Were the IRMD insider stock sales made under a Rule 10b5-1 plan?

Yes, the reported sales were made under a Rule 10b5-1 plan. The filing states they were effected pursuant to a pre-arranged trading plan adopted by the reporting person on November 5, 2025, indicating the transactions were scheduled in advance.

How many IRMD shares does the Phillip Susi 2008 Dynasty Trust hold after the sales?

The Phillip Susi 2008 Dynasty Trust reported holding 2,164,600 shares. This post-transaction balance reflects the remaining Common Stock held indirectly after selling 2,500 shares on June 1, 2026, as disclosed in the Form 4.

What other indirect IRMD holdings are reported for Roger E. Susi?

Two additional trusts report indirect IRADIMED holdings. The Matthew Susi 2008 Dynasty Trust holds 2,062,500 shares and the Roger E. Susi Revocable Trust holds 162,950 shares of Common Stock, as reported in the same Form 4 filing.

Does Roger E. Susi claim full beneficial ownership of the IRMD trust shares?

No, full beneficial ownership is expressly disclaimed. The filing states Susi disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest, limiting how these indirect holdings are attributed to him under Section 16.